Daxor receives FDA clearance for new BVA system

Daxor (DXR) Corporation announces FDA 510(k) clearance for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer, BVA. The new Daxor BVA device quantifies a patient’s blood volume against patient-specific norms, enabling precise fluid management across a broad spectrum of clinical conditions affecting millions of patients each year.